BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Engineers Gate Manager LP

Key Points

• Engineers Gate Manager LP reduced its BioMarin stake by 58.4% in the second quarter, selling 255,213 shares and retaining 181,647 shares valued at approximately $10.4 million.
• BioMarin reported quarterly revenue of $989.7 million and earnings of $1.20 per share, exceeding analyst estimates; revenue increased 20% year over year.
• Analysts maintain a generally positive outlook, with the stock rated “Moderate Buy” and an average price target of $89.17 versus a recent price of $65.51, although HC Wainwright remains neutral with a $60 target.

Engineers Gate Manager LP cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 58.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 181,647 shares of the biotechnology company's stock after selling 255,213 shares during the quarter. Engineers Gate Manager LP owned about 0.09% of BioMarin Pharmaceutical worth $10,394,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Parkside Financial Bank & Trust increased its position in BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 187 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $39,000. CIBC Private Wealth Group LLC raised its position in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock valued at $39,000 after buying an additional 179 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in BioMarin Pharmaceutical in the third quarter valued at approximately $40,000. Finally, Parallel Advisors LLC grew its position in BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 295 shares during the period. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Up 1.7%

NASDAQ BMRN opened at $65.51 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm has a market cap of $12.68 billion, a price-to-earnings ratio of 177.05, a PEG ratio of 0.46 and a beta of 0.24. The firm has a 50 day simple moving average of $63.16 and a 200-day simple moving average of $58.45. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. During the same period in the prior year, the firm earned $1.44 EPS. The firm's revenue for the quarter was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on BMRN. Morgan Stanley lifted their target price on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. UBS Group set a $88.00 target price on shares of BioMarin Pharmaceutical in a research report on Wednesday, August 26th. Oppenheimer lifted their price target on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an "outperform" rating in a research report on Friday, August 7th. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Citigroup increased their price objective on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $89.17.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Positive Phase 3 VOXZOGO data: BioMarin reported that the CANOPY-HCH-3 study in children with hypochondroplasia achieved statistically significant improvements in annualized growth velocity, standing height, height Z-score and arm span. The results were published in NEJM Evidence and presented at the ESPE 2026 meeting, strengthening the case for expanding VOXZOGO’s addressable market. BioMarin Announces Positive Results of Phase 3 VOXZOGO Study
• Positive Sentiment: Regulatory expansion opportunity: BioMarin recently submitted a supplemental New Drug Application to the FDA seeking approval to use VOXZOGO in children with hypochondroplasia. Successful review could broaden the product’s commercial opportunity and support investor sentiment. BioMarin’s VOXZOGO Hits Phase 3 Growth Endpoint
• Neutral Sentiment: Investor conference updates: BioMarin presented at the Citigroup, Cantor Fitzgerald and Wells Fargo healthcare conferences. The transcripts provide additional management commentary on the pipeline and business outlook, but the supplied reports do not identify a new material financial or clinical announcement. Citigroup conference transcript
• Neutral Sentiment: Short-interest report appears unreliable: The report lists short interest at zero shares and a zero-day days-to-cover ratio, offering no meaningful bearish or bullish signal and likely reflecting a data-quality issue.
• Negative Sentiment: Analyst remains cautious: HC Wainwright reaffirmed a “neutral” rating and assigned a $60 price target, below the referenced $65.51 share price. That implies potential downside and signals skepticism about near-term valuation or execution. HC Wainwright analyst rating

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.

BioMarin's marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.